Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial

2020 ◽  
Vol 41 (5) ◽  
pp. 1183-1192 ◽  
Author(s):  
Zeinab Ghorbani ◽  
Mansoureh Togha ◽  
Pegah Rafiee ◽  
Zeynab Sadat Ahmadi ◽  
Reyhaneh Rasekh Magham ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Vitamin D3

scholarly journals Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial

2018 ◽  
Vol 74 (1) ◽  
pp. 91-98 ◽  
Author(s):  
Li Chen ◽  
Yanbin Dong ◽  
Jigar Bhagatwala ◽  
Anas Raed ◽  
Ying Huang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dna Methylation ◽  
Vitamin D ◽  
African Americans ◽  
Randomized Clinical Trial ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
P Value ◽  
Epigenetic Aging ◽  
Vitamin D3 Supplementation

Abstract Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (∆Age) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value = .046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value = .044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ∆Age only (p values = .002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

Effects of vitamin D3-fortified low-fat yogurt and milk on serum cytokine levels and anti hsp-27 antibody titer in adults with abdominal obesity: A randomized clinical trial

2021 ◽  
pp. 100382
Author(s):  
Fatemeh Najar Sedgh Doust ◽  
Payam Sharifan ◽  
Mahya Razmi ◽  
Mansoureh Sadat Ekhteraei Toussi ◽  
Niloofar Taghizadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Antibody Titer ◽  
Abdominal Obesity ◽  
Vitamin D3 ◽  
Serum Cytokine ◽  
Low Fat ◽  
Hsp 27 ◽  
Cytokine Levels

scholarly journals Can probiotic fermented milk products prevent early and late complications of antibiotic therapy in young children? (Results of an open randomized clinical trial)

2021 ◽  
Author(s):  
А.И. Хавкин ◽  
М.М. Гурова ◽  
В.П. Новикова ◽  
О.Б. Федотова ◽  
Д.В. Макаркин ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Antibiotic Therapy ◽  
Randomized Clinical Trial ◽  
Vitamin D3 ◽  
Lactobacillus Acidophilus ◽  
Acute Respiratory Infection ◽  
Fermented Milk ◽  
Late Complications ◽  
Gastrointestinal Disorders ◽  
Bifidobacterium Animalis

Представлены результаты мультицентрового открытого рандомизированного клинического исследования, цель которого заключалась в оценке протективных свойств кисломолочного пробиотического напитка, содержащего штаммы Lactobacillus acidophilus и Bifidobacterium animalis subsp. lactis (BB-12), обогащенного пребиотиком (инулин), цинком, кальцием и витамином D3 для профилактики развития ранних и поздних осложнений антибактериальной терапии у детей от 8 до 36 месяцев с острой респираторной инфекцией. В задачи исследования входило определение частоты развития и выраженности желудочно-кишечных расстройств в зависимости от включения в рацион питания пробиотического кисломолочного напитка для ежедневного употребления в течение трех месяцев. Показана информативность использования Брюссельской шкалы форм кала (BITSS) для детей раннего возраста при оценке характера стула у детей с острой респираторной инфекцией, получивших курс антибактериальной терапии. Установлено, что прием кисломолочного пробиотического напитка, содержащего Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis, инулин, цинк, кальций и витамин D3, в течение трех месяцев, начиная с первого дня антибактериальной терапии, способствует поддержанию стабильности консистенции кала в ходе лечения и в период восстановления после него снижает частоту развития желудочно-кишечных расстройств, риск развития ранних и поздних осложнений, связанных с приемом антибиотиков. The paper presents the results of a multicenter, open, randomized clinical trial aimed at assessing the protective properties of a fermented milk probiotic drink containing Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis (BB-12), enriched with prebiotic (inulin), zinc, calcium and vitamin D3 to prevent the development of early and late complications of antibiotic therapy in children aged 8 to 36 months with acute respiratory infection. The objectives of the study were to determine the incidence and severity of gastrointestinal disorders depending on the inclusion in the diet of a probiotic fermented milk drink for daily use for three months. The informative value of using the Brussels Infant and Toddler Stool Scale (BITSS) for young children in assessing the nature of stool in children with acute respiratory infection who received a course of antibiotic therapy was shown. It was found that taking a fermented milk probiotic drink containing Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis, inulin, zinc, calcium and vitamin D3 for three months, starting from the first day of antibiotic therapy, helps to maintain the stability of the consistency of feces during treatment and during the recovery period after it reduces the incidence of gastrointestinal disorders, the risk of early and late complications associated with taking antibiotics.

scholarly journals Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2170
Author(s):  
Shaun Sabico ◽  
Mushira A. Enani ◽  
Eman Sheshah ◽  
Naji J. Aljohani ◽  
Dara A. Aldisi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin D ◽  
Randomized Clinical Trial ◽  
Vitamin D3 ◽  
Sensory Loss ◽  
Vitamin D Status ◽  
Oral Vitamin ◽  
Increased Risk ◽  
Vitamin D3 Supplementation ◽  
Group Comparisons

Objective: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects of 5000 IU versus 1000 IU daily oral vitamin D3 supplementation in the recovery of symptoms and other clinical parameters among mild to moderate COVID-19 patients with sub-optimal vitamin D status. Study Design and Setting: A total of 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for mild to moderate COVID-19 disease were allocated to receive once daily for 2 weeks either 5000 IU oral vitamin D3 (n = 36, 21 males; 15 females) or 1000 IU oral vitamin D3 (standard control) (n = 33, 13 males; 20 females). Anthropometrics were measured and blood samples were taken pre- and post-supplementation. Fasting blood glucose, lipids, serum 25(OH)D, and inflammatory markers were measured. COVID-19 symptoms were noted on admission and monitored until full recovery. Results: Vitamin D supplementation for 2 weeks caused a significant increase in serum 25(OH)D levels in the 5000 IU group only (adjusted p = 0.003). Within-group comparisons also showed a significant decrease in BMI and IL-6 levels overtime in both groups (p-values < 0.05) but was not clinically significant in between-group comparisons. Kaplan–Meier survival analysis revealed that the 5000 IU group had a significantly shorter time to recovery (days) than the 1000 IU group in resolving cough, even after adjusting for age, sex, baseline BMI, and D-dimer (6.2 ± 0.8 versus 9.1 ± 0.8; p = 0.039), and ageusia (loss of taste) (11.4 ± 1.0 versus 16.9 ± 1.7; p = 0.035). Conclusion: A 5000 IU daily oral vitamin D3 supplementation for 2 weeks reduces the time to recovery for cough and gustatory sensory loss among patients with sub-optimal vitamin D status and mild to moderate COVID-19 symptoms. The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.

Sign in / Sign up

Export Citation Format

Share Document